Dexamethasone suppression test in major and minor depressive disorders

Area of Science:

• Neuroscience
• Psychiatry
• Endocrinology

Background:

• Major and minor depressive disorders represent significant clinical challenges.
• Accurate differential diagnosis is crucial for effective treatment selection.
• The dexamethasone suppression test (DST) is a neuroendocrine challenge test with potential diagnostic utility.

Purpose of the Study:

• To evaluate the diagnostic validity of the dexamethasone suppression test (DST) for differentiating major depressive disorder from minor depressive disorder.
• To assess the sensitivity, specificity, and predictive value of the DST in a clinical outpatient sample.

Main Methods:

• Thirty-eight outpatients were classified using the Research Diagnostic Criteria (Spitzer et al., 1978): 14 with major depression, 14 with minor depression, and 10 healthy controls.
• Participants underwent the DST, involving administration of 2 mg dexamethasone at midnight.
• Plasma cortisol levels were measured at 4 p.m. and 11:00 p.m. post-dexamethasone administration.

Main Results:

• Six out of 14 (43%) patients with major depressive disorder exhibited an abnormal DST response (elevated plasma cortisol).
• None of the 14 patients with minor depressive disorder showed an abnormal DST response.
• All 10 healthy controls demonstrated a normal DST response.

Conclusions:

• The dexamethasone suppression test demonstrated 100% specificity in distinguishing between major depressive disorder and both minor depressive disorder and healthy controls.
• The DST has a sensitivity of 43% for major depressive disorder, suggesting its utility as a diagnostic aid.
• The test exhibits a high predictive value, supporting its role in the differential diagnosis of depressive disorders.